Sipuleucel-T is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Sipuleucel-T becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about NationDrugs.to
List of countries where we can ship Sipuleucel-T:
Latest news releases on Sipuleucel-T:
Sipuleucel-T (APC8015, trade name Provenge), developed by Dendreon Corporation, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is a personalized ...
This page contains brief information about sipuleucel-T and a collection of links to more information about the use of this vaccine, research results, and ongoing ...
Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic ...
PROVENGE is the only personalized immunotherapy for advanced prostate cancer. PROVENGE can activate your immune system to seek out and attack advanced prostate cancer.
CLINICAL PHARMACOLOGY. The development of sipuleucel-T vaccine was based on the concept of antigen-presenting cells (APCs). These cells “present” antigens in a ...
Easy-to-read patient leaflet for Sipuleucel-T. Includes indications, proper use, special instructions, precautions, and possible side effects.
Provenge (sipuleucel-T) is an immunotherapy to treat patients with advanced prostate cancer who have little or no pain. It was approved by the FDA in 2010.
Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have ...
Get YouTube without the ads. Working... No thanks 1 month free. Find out why Close. DENDREON PROVENGE Mechanism of Action Prostate Oncology Specialists.
Learn how PROVENGE (sipuleucel-T) immunotherapy is different from other prostate cancer treatments. Discuss your treatment options with your urologist or oncologist.